A semi-mechanistic exposure–response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases

Verinurad, a uric acid transporter 1 (URAT1) inhibitor, lowers serum uric acid by promoting its urinary excretion. Co-administration with a xanthine oxidase inhibitor (XOI) to simultaneously reduce uric acid production rate reduces the potential for renal tubular precipitation of uric acid, which ca...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Pharmacokinet Pharmacodyn
Hlavní autoři: Leander, Jacob, Sunnåker, Mikael, Rekić, Dinko, Aksenov, Sergey, Eriksson, Ulf G., Johansson, Susanne, Parkinson, Joanna
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer US 2021
Témata:
Original Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8225519/
https://ncbi.nlm.nih.gov/pubmed/33728547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10928-021-09747-y
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky